X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (135) 135
middle aged (97) 97
male (95) 95
adult (93) 93
female (90) 90
hematology (84) 84
aged (68) 68
adolescent (54) 54
index medicus (51) 51
treatment outcome (41) 41
therapy (34) 34
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
oncology (30) 30
risk factors (27) 27
chemotherapy (26) 26
retrospective studies (23) 23
young adult (23) 23
aged, 80 and over (22) 22
follow-up studies (21) 21
prognosis (19) 19
remission induction (19) 19
benzamides (18) 18
cancer (18) 18
imatinib mesylate (18) 18
antineoplastic agents - therapeutic use (17) 17
recurrence (17) 17
disease-free survival (15) 15
prospective studies (15) 15
survival rate (14) 14
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (13) 13
transplantation (13) 13
leukemia (12) 12
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (12) 12
survival (12) 12
survival analysis (12) 12
disease (11) 11
hematopoietic stem cell transplantation (11) 11
child (10) 10
combined modality therapy (10) 10
cytarabine - administration & dosage (10) 10
idarubicin (10) 10
idarubicin - administration & dosage (10) 10
lymphoma (10) 10
piperazines - therapeutic use (10) 10
pyrimidines - therapeutic use (10) 10
abridged index medicus (9) 9
drug administration schedule (9) 9
remission (9) 9
settore med/15 - malattie del sangue (9) 9
thrombosis (9) 9
time factors (9) 9
transplantation, homologous (9) 9
antineoplastic agents - administration & dosage (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
cyclophosphamide - administration & dosage (8) 8
diagnosis (8) 8
essential thrombocythemia (8) 8
hematology, oncology and palliative medicine (8) 8
medicine & public health (8) 8
risk (8) 8
thrombosis - etiology (8) 8
acute myeloid-leukemia (7) 7
analysis (7) 7
antineoplastic agents - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
care and treatment (7) 7
classification (7) 7
leukocyte count (7) 7
medicine, general & internal (7) 7
minimal residual disease (7) 7
non-hodgkins-lymphoma (7) 7
rituximab (7) 7
stem-cell transplantation (7) 7
vincristine - administration & dosage (7) 7
acute disease (6) 6
adults (6) 6
bone-marrow-transplantation (6) 6
child, preschool (6) 6
expression (6) 6
health aspects (6) 6
hemic and lymphatic diseases (6) 6
imatinib (6) 6
italy - epidemiology (6) 6
leukemia - drug therapy (6) 6
mutation (6) 6
myelodysplastic syndromes (6) 6
peripheral vascular disease (6) 6
piperazines - administration & dosage (6) 6
piperazines - adverse effects (6) 6
polycythemia-vera (6) 6
polymerase-chain-reaction (6) 6
prednisone - therapeutic use (6) 6
pyrimidines - administration & dosage (6) 6
pyrimidines - adverse effects (6) 6
recombinant proteins (6) 6
reverse transcriptase polymerase chain reaction (6) 6
salvage therapy (6) 6
stem cell transplantation (6) 6
thrombocythemia, essential - complications (6) 6
trial (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2011, Volume 364, Issue 8, pp. 775 - 776
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease
Journal Article
Nature Genetics, ISSN 1061-4036, 01/2013, Volume 45, Issue 1, pp. 18 - 24
Journal Article
Annals of Hematology, ISSN 0939-5555, 06/2010, Volume 89, Issue 6, pp. 591 - 596
Journal Article
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2009, Volume 15, Issue 15, pp. 5002 - 5007
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2015, Volume 15, Issue 4, pp. 208 - 213
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2012, Volume 87, Issue 5, pp. 552 - 554
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 6, pp. 605 - 612
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2003, Volume 9, Issue 2, pp. 625 - 632
Purpose: Imatinib (Glivec) is a potent inhibitor of bcr/abl, an oncogenic fusion protein that causes chronic myelogenous leukemia (CML). α1 acid glycoprotein... 
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2015, Volume 90, Issue 5, pp. E80 - E85
Journal Article
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 04/2011, Volume 103, Issue 7, pp. 553 - 561